Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 718

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 3
Chunk 718
---
 than the registration statement registering
the shares underlying the Replacement Warrants).

In connection with the
transactions contemplated in the Agreement, the Company agreed to pay its placement agent, Maxim Group, LLC (the “Agent”)
the following compensation, (i) a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated
by the Agreement, and (ii) legal fees and out-of-pocket expenses of $15,000.

May 2024 Public Offering

On May 17, 2024,
the Company closed a public offering pursuant to which it sold an aggregate of: (i) 306,250 shares
of common stock and accompanying Class A warrants to purchase up to 306,250 shares
of common stock and Class B warrants to purchase up to 306,250 shares
of common stock, at a combined public offering price of $4.64
per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 706,250 shares
of common stock and accompanying Class A warrants to purchase up to 706,250
shares of common stock and Class B warrants to purchase up to 706,250
shares of common stock, at a combined public offering price of $0.4.63 per pre-funded warrant and accompanying warrants, which is
equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of
each such pre-funded warrant.

All pre-funded
warrants issued in the offering were exercised in the quarter ended June 30, 2024. The Class A
and Class B warrants each have an exercise price of $4.64 per
share, are immediately exercisable, and, in the case of Class A warrants, will expire on May
17, 2029, and in the case of Class B warrants, will expire
on May
19, 2025. The exercise price of the Class A and Class B warrants
is also subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in such
warrants.

Maxim Group LLC (“Maxim”),
served as the exclusive placement agent in connection with the offering. We paid Maxim a cash fee of 6.5% of the aggregate gross proceeds
raised at the closing of the offering, and reimbursement of certain expenses and legal fees in the amount of $100,000.